Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study ID
NCT05597202
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide, 2.0 mg/mL — DRUG
    Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.

Study Details

To study the effect of type 2 diabetes (T2D) on vascular wall inflammation and hematopoietic stem cell composition in vivo, and whether these changes can be reversed with glucagon like peptide 1 receptor (GLP1R)-agonism.

Key Dates

Start date
Jan 1, 2023
Status verified
May 2023
Primary completion
Mar 31, 2024
Completion
Apr 30, 2024

Study Design

Enrollment
22 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment arm
    Will receive semaglutide treatment for 6 months, at the highest tolerable dose, up to a maximum of 2.0mg weekly.

Primary Outcome Measure

Difference in coronary 68Ga-Dotatate uptake after treatment. [ Time Frame: 6 months ]

Central Contacts

Related Studies